支持

  • 哪里購買
  • 選擇您的所在地

足球网站制作毕业论文:循環腫瘤細胞

  熱門產品
循環腫瘤細胞 (CTCs)
循環腫瘤細胞 (CTCs)是來自原發腫瘤并進入外周血液循環的腫瘤細胞,這些細胞從原發腫瘤蔓延至其它部位,進而導致癌癥轉移。循環腫瘤細胞存在于癌癥患者的外周血液中,檢測 CTCs 可幫助確定轉移過程。與其它血液細胞不同,血液中 CTCs 的數量極少,因而使其難以檢測。

但開發血液 CTCs 檢測和分析方法仍至關重要,原因在于這些細胞有助于癌癥研究和癌癥患者的臨床分析,其在進展診斷和治療監測中扮演著關鍵角色。

為了將 CTC 與血液中的所有其它細胞相區分,利用以下特征鑒別 CTC:
  • 細胞標志物:
    • 陽性:cell-surface vimentin (CSV), EpCAM, Cytokeratin 8, Cytokeratin 18, or Cytokeratin 19
    • 陰性:CD45
  • 形態學:
    • 大?。褐遼?4 µm x 4 µm
    • 細胞核

CTCs 研究簡介
實施 CTCs 研究的第一步是有效分離 CTCs。以下為數種分離方法:
  • 基于形態學方法,
    • 梯度密度
    • 大小
    • 生物形態學(大小和變形性)
  • 免疫學方法,包括
    • 免疫磁珠方法
    • 微流裝置

隨后可采用細胞術方法和核酸法根據其結果特征鑒別 CTCs:
  • 細胞術方法
    • ICC(免疫細胞化學)
    • IF(免疫熒光法)
    • FISH(原位雜交熒光法)
    • 流式細胞術
  • 核酸法
    • RT-PCR

 
系統

CytoQuest? CR - 循環罕見細胞陽性富集與收集系統

幼儿园足球教案 www.vxwgk.com 亞諾法的 CytoQuest? CR 是用于循環罕見細胞 (CRC) 捕捉、計數、富集和收集的系統。在轉化和臨床研究中的三個主要CRC亞型為循環腫瘤細胞 (CTC)、循環祖細胞 (CPC) 和循環胎兒細胞 (CFC)。CRC在市場是否能被采用,取決于下列因素: 1.有效和可重現的識別2. 單細胞分離 3. 高純度富集及具活性的細胞,而使用的試劑和耗材上則需達GMP等級的規格。

更多關于CytoQuest? CR的信息
 
產品展示

Cancer Metastasis Ab   Circulating Tumor Cell Ab
2000+ antibodies targeting proteins related to cancer metastasis. 350+ antibodies for CSV, CD45, cytokeratins and EMT markers.
 
文獻/支持性資料

  • Highlights
  • 1. EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression.
    Satelli A, Batth I, Brownlee Z, Mitra A, Zhou S, Noh, H, Rojas CR, Li H, Meng QH, Li S. Oncotarget. 2017.
    2. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.
    Batth IS, Mitra A, Manier S, Ghobrial IM, Menter D, Kopetz S, Li S. Ann Oncol. 2016 Dec 28(3): 468-77.
    3. Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients.
    Satelli A, Batth IS, Brownlee Z, Rojas C, Meng QH, Kopetz S, Li S. Sci Rep. 2016 Jul 1;6:28910.
    4. Cell-surface Vimentin: A mislocalized protein for isolating csVimentin+ CD133- novel stem-like hepatocellular carcinoma cells expressing EMT markers.
    Mitra A, Satelli A, Xia X, Cutrera J, Mishra L, Li S. Int J Cancer. 2015 Jul 15;137(2):491-6.
    5. EMT, CTCs and CSCs in tumor relapse and drug-resistance.
    Mitra A, Mishra L, Li S. Oncotarget. 2015 May 8;6(13):10697-711.
    6. Epithelial–Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression.
    Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH, Li S. Clin Cancer Res. 2015 Feb 15;21(4):899-906.
    7. Circulating Tumor Cell Enumeration with a Combination of Epithelial Cell Adhesion Molecule– and Cell-Surface Vimentin–Based Methods for Monitoring Breast Cancer Therapeutic Response.
    Satelli A, Brownlee Z, Mitra A, Meng QH, Li S. Clin Chem. 2015 Jan 1;61(1):259-66.
    8. Vimentin in cancer and its potential as a molecular target for cancer therapy.
    Satelli A, Li S. Cell Mol Life Sci. 2011 Sep;68(18):3033-46.

     

  • 技術
  • 1. Microdevice for the isolation and enumeration of cancer cells from blood.
    Tan SJ, Lakshmi RL, Chen P, Lim WT, Yobas L, Lim CT. Biosens Bioelectron. 2010 Dec 15;26(4):1701-5.
    2. Versatile label free biochip for the detection of circulation tumor cells from peripheral blood in cancer patients.
    Tan SJ, Yobas L, Lee GY, Ong CN, Lim CT. Biomed Microdevices. 2009 Aug;11(4):883-92.

     

  • 轉化研究
  • 1. Epithelial-mesenchymal transition and cell cooperativity in metastasis.
    Tsuji T, Ibaragi S, Hu GF. Cancer Res. 2009 Sep 15;69(18):7135-9.
    2. Molecular aspects of tumor cell migration and invasion.
    Bozzuto G, Ruggieri P, Molinari A. Ann Ist Super Sanita. 2010;46(1):66-80.
    3. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients.
    Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Breast Cancer Res. 2009;11(4):R46.

     

  • 臨床前研究
  • 1. Circulation tumor cells are transcriptionally similar to primary tumor in a murine prostate model.
    Helzer KT, Barnes HE, Day L, Harvey J, Billings PR, Forsyth A. Cancer Res. 2009 Oct 1;69(19):7860-6.
    2. Systemic spread is an early step in breast cancer.
    Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmuller G, Klein CA. Cancer Cell. 2008 Jan;13(1):58-68.
    3. Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor-and metastasis-initiating cells and their progenies.
    Mimeault M, Batra SK. Anticancer Agents Med Chem. 2010 Feb;10(2):137-51.

     

  • 臨床研究
  • 1. Utilizing circulating tumor cells: challenges and pitfalls.
    Attard G, de Bono JS. Curr Opin Genet Dev. 2011 Feb;21(1):50-8.
    2. Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance.
    Sun YF, Yang XR, Zhou J, Qiu SJ, Fan J, Xu Y. J Cancer Res Clin Oncol. 2011 Aug;137(8):1151-73.

     

  • Clinical Application (FDA Approved)
  • 1. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.
    de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D. Clin Cancer Res. 2008 Oct 1;14(19):6302-9.
    2. Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
    Cristofanilli M. Semin Oncol. 2006 Jun;33(3 Suppl 9):S9-14.
    3. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
    Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ. J Clin Oncol. 2008 Jul 1;26(19):3213-21.

     

    • RSS
    • YouTube
    • Linkedin
    • Facebook